Skip to content

Message from Our Chairman and CEO

To Our Global Community:

We all know from firsthand experience that 2020 was a year of profound upheaval and uncertainty. It was also, however, a clarifying moment for us at Johnson & Johnson.

As we grappled with the wide-ranging impacts of the COVID-19 pandemic and the ongoing economic volatility that threw into stark relief the issues of racial injustice and health inequities, one thing was certain: when it comes to global public health, the stakes could not be higher. While solving the most pressing global health challenges is never easy, the once-in-a-generation confluence of these crises underscored the complexity that organizations like ours must navigate if we truly want to make the maximum positive impact on human health.

At Johnson & Johnson, taking on even the most daunting healthcare challenges has been at the core of who we are for 135 years. And while living up to our commitments embodied in Our Credo has always required constant evolution and innovation, the last year demanded that we embrace radically new ways of doing business and even greater heights of purpose-driven collaboration through public–private partnerships.

As we detail in this Report, the significant challenges of 2020 did not deter us from accomplishing many of our key goals.

While much of the world’s attention was on our leadership in the fight against the COVID-19 pandemic—culminating in the deployment of our Janssen COVID-19 vaccine this year—we also achieved our Health for Humanity 2020 Goals of fighting HIV and tuberculosis, as well as accelerating broader access to our Ebola vaccine for those most in need. We brought this same agility to our work on behalf of our patients and customers in areas as diverse as advancing the science around the treatment of multiple myeloma, deploying technological innovations and application of data science to safeguard critically important supply chains, and launching a first-of-its-kind medical device for the management of persistent atrial fibrillation. Delivering on our responsibilities to a healthy planet, we made progress on reducing our carbon footprint, including achieving more than 50% use of renewable electricity globally.

Throughout 2020, bearing witness to the way the pandemic revealed weaknesses in our public health systems and pushed businesses to do more to create healthier, more equitable communities was sometimes a humbling experience—but it was also an inspiration.

I’m pleased to be able to say that these challenges of 2020 only enhanced our commitment to—and continued focus on—creating long-term value for all stakeholders by integrating social considerations, environmental sustainability, and good governance into every aspect of our business. From launching the Our Race to Health Equity platform to address the root causes of healthcare inequity in the United States, to deepening our commitments to address complex issues like smoking cessation, to environmental health innovations to make our packaging easier to recycle or reuse through the Healthy Lives initiative from Johnson & Johnson Consumer Health, we have kept our sights firmly set on catalyzing lasting change.

Alex Gorsky connecting with employees during a virtual visit to our Shanghai and Beijing offices.

To help lead the world into a brighter post-COVID-19 future where healthier families flourish in healthier societies on a healthier planet, we know we must capitalize on the incredible momentum we’ve unleashed at Johnson & Johnson this past year.

Building on our Health for Humanity 2020 Goals—the successes and shortcomings of which are detailed in this Report—we are launching even more ambitious goals for 2025 that will enable us to continue living into Our Purpose as we make further contributions to 11 of the 17 United Nations 2030 Sustainable Development Goals. Given how essential collaboration was to our shared progress in 2020, we’re actively expanding on many of our historic partnerships across the entire healthcare ecosystem to take on the challenges of tomorrow. And, as always, we will hold ourselves to a high level of transparency and accountability through reports such as this one and our annual Janssen U.S. Transparency Report.

I know we will continue to do our part through whatever unknowable new challenges and upheavals lie ahead, because we will always be able to draw upon our ultimate strength: the remarkable people of Johnson & Johnson. In an extraordinary year, our 136,000-plus global employees embraced radically new ways of working with greater agility than ever before. Each individual’s ingenuity and resilience are what allowed us to go above and beyond for all our stakeholders. I could not be prouder of what Johnson & Johnson employees showed the world is possible—or more optimistic about what their passion and perseverance will help us achieve in the future.

Alex Gorsky
Chairman, Board of Directors
and Chief Executive Officer

Back to Our Approach Up next Year in Brief
Back to Top
You are leaving and entering a third-party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties.
Yes, let's go